Introduction
CiMaas develops immunotherapy for cancer by optimally engaging the immune system.
Read more about CiMaas Immunotherapy products,
or watch our video.
CiMaas will present the company at BIO Capital Europe 2019 in Amsterdam. BIO Capital Europe is a meeting place for investors and life science companies.
CiMaas will present its strategy and progress on March 14 at 5 PM.
CiMaas recently applied for a classification for its’ Advanced Therapeutic Medicinal Product, adoptive NK cell therapy for multiple myeloma.
Upon this request, the European Medicines Agency / Committee for Advanced Therapies considers that product NK-Xpand-MM1 falls within the definition of somatic cell therapy medicinal product, as provided in Article 2 of Regulation (EC) No 1394/2007.
This classification marks the first step of the regulatory pathway CiMaas has taken to obtain the manufacturing license to produce Natural Killer cells in its’ planned clinical trial for patients with multiple myeloma.
Mercurius Heerlen B.V. and Werker Beleggingsmaatschappij B.V. invested a second round in CiMaas B.V. to realize cancer immunotherapy.
This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.
This brings CiMaas again a step closer to fund its’ development of cellular therapies into clinical trials for the patients with multiple myeloma and lung cancer.